Cargando…

Virus-Vectored Ebola Vaccines

The Ebola virus disease (EVD) is one of the most dangerous infections affecting humans and animals. The first EVD outbreaks occurred in 1976 in Sudan and Zaire. Since then, more than 20 outbreaks have occurred; the largest of which (2014−2016) evolved into an epidemic in West Africa and claimed the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dolzhikova, I.V., Tokarskaya, E.A., Dzharullaeva, A. S., Tukhvatulin, A. I., Shcheblyakov, D. V., Voronina, O.L., Syromyatnikova, S. I., Borisevich, S. V., Pantyukhov, V. B., Babira, V. F., Kolobukhina, L. V., Naroditsky, B. S., Logunov, D. Y., Gintsburg, A. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	A.I. Gordeyev 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662269/ https://www.ncbi.nlm.nih.gov/pubmed/29104771

Ejemplares similares

Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia
por: Dolzhikova, I. V., et al.
Publicado: (2017)

Nanobodies Are Potential Therapeutic Agents for the Ebola Virus Infection
por: Esmagambetov, I. B., et al.
Publicado: (2021)

Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein
por: Ozharovskaia, T. A., et al.
Publicado: (2019)

Toll-Like Receptors (TLRs): The Role in Tumor Progression
por: Shcheblyakov, D.V., et al.
Publicado: (2010)

Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses
por: Tukhvatulin, Amir I., et al.
Publicado: (2016)

NOD1/2 and the C-Type Lectin Receptors Dectin-1 and Mincle Synergistically Enhance Proinflammatory Reactions Both In Vitro and In Vivo
por: Tukhvatulin, Amir I, et al.
Publicado: (2020)

Stimulation of Dectin-1 and Dectin-2 during Parenteral Immunization, but Not Mincle, Induces Secretory IgA in Intestinal Mucosa
por: Dzharullaeva, Alina S., et al.
Publicado: (2018)

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
por: Logunov, Denis Y, et al.
Publicado: (2020)

Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis
por: Burmistrova, Daria A., et al.
Publicado: (2016)

Preclinical Studies of Immunogenity, Protectivity, and Safety of the Combined Vector Vaccine for Prevention of the Middle East Respiratory Syndrome
por: Dolzhikova, I. V., et al.
Publicado: (2020)

Triggering of Toll-like Receptor-2 in Mouse Myelomonocytic Leukaemia Cells WEHI-3B Leads to the Suppression of Apoptosis and Promotes Tumor Progression in Vivo
por: Shcheblyakov, D.V., et al.
Publicado: (2011)

Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection
por: Voronina, Daria V., et al.
Publicado: (2022)

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults
por: Tukhvatulin, Amir I., et al.
Publicado: (2021)

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
por: Logunov, Denis Y, et al.
Publicado: (2021)

Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice
por: Godakova, Svetlana A., et al.
Publicado: (2019)

Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study
por: Tukhvatulin, Amir I., et al.
Publicado: (2023)

Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors’ reply
por: Logunov, Denis Y, et al.
Publicado: (2020)

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
por: Favorskaya, Irina A., et al.
Publicado: (2022)

An Efficient Method for the Delivery of the Interleukin-2 Gene to Human Hematopoietic Cells using the  Fiber-Modified Recombinant Adenovirus
por: Rogozhin, V.N., et al.
Publicado: (2011)

Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial – Authors' reply
por: Logunov, Denis Y, et al.
Publicado: (2021)

Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
por: Tukhvatulin, Amir I., et al.
Publicado: (2022)

Adjuvantation of an Influenza Hemagglutinin Antigen with TLR4 and NOD2 Agonists Encapsulated in Poly(D,L-Lactide-Co-Glycolide) Nanoparticles Enhances Immunogenicity and Protection against Lethal Influenza Virus Infection in Mice
por: Tukhvatulin, Amir, et al.
Publicado: (2020)

A In Vitro and In Vivo Study of the Ability of NOD1 Ligands to Activate the Transcriptional Factor NF-kB
por: Tukhvatulin, A.I., et al.
Publicado: (2011)

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
por: Fomina, Daria S., et al.
Publicado: (2023)

Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection
por: Koroleva, Ekaterina A., et al.
Publicado: (2017)

rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
por: Esmagambetov, Ilias B., et al.
Publicado: (2023)

Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals
por: Lapa, Daniele, et al.
Publicado: (2022)

rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis
por: Derkaev, Artem A., et al.
Publicado: (2022)

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants
por: Gushchin, Vladimir A., et al.
Publicado: (2021)

Regulation of the Target Protein (Transgene) Expression in the Adenovirus Vector Using Agonists of Toll-Like Receptors
por: Bagaev, A. V., et al.
Publicado: (2014)

Construction of a pIX-modified Adenovirus Vector Able to Effectively Bind to Nanoantibodies for Targeting
por: Garas, M. N., et al.
Publicado: (2014)

Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A
por: Panova, Eugenia A., et al.
Publicado: (2023)

Induction of a Protective Heterosubtypic Immune Response Against the Influenza Virus by using Recombinant Adenoviral Vectors Expressing Hemagglutinin of the Influenza H5 Virus
por: Shmarov, M.M., et al.
Publicado: (2010)

Development of Neutralizing Nanobodies to the Hemagglutinin Stem Domain of Influenza A Viruses
por: Voronina, D. V., et al.
Publicado: (2021)

Non-thermal Plasma Causes p53-Dependent Apoptosis in Human Colon Carcinoma Cells
por: Tuhvatulin, A.I., et al.
Publicado: (2012)

Effective Genetic Expression of Nanoantibodies by Recombinant Adenoviral Vector in vitro
por: Gribova, I.Yu., et al.
Publicado: (2011)

Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy
por: Gushchin, Vladimir A., et al.
Publicado: (2022)

Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus
por: Gushchin, Vladimir A., et al.
Publicado: (2022)

Integrated into Environmental Biofilm Chromobacterium vaccinii Survives Winter with Support of Bacterial Community
por: Egorova, Daria A., et al.
Publicado: (2020)

A Deep Look Into COVID-19 Severity Through Dynamic Changes in Blood Cytokine Levels
por: Kleymenov, Denis A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vficva2i99r1a8853it8cbqjv6